1.	An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma Phase: Phase IV Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CR101862, PCI-32765MCL4001, NCT01833039
2.	A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CR100840, PCI-32765CLL3001, 2012-000600-15, U1111-1135-3745, NCT01611090
3.	Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CR100848, PCI-32765MCL3001, 2012-000601-74, U1111-1135-6930, NCT01646021
4.	A Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 Versus Chlorambucil in Patients 65 Years or Older With Treatment-naive Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (RESONATE™-2) Phase: Phase III Type: Treatment Status: Active Age: 65 and over Sponsor: Pharmaceutical / Industry Protocol IDs: PCYC-1115-CA, 2012-003967-23, NCT01722487
5.	An Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Participated in Study PCYC-1115-CA (PCI-32765 Versus Chlorambucil) Phase: Phase III Type: Treatment Status: Active Age: 65 and over Sponsor: Pharmaceutical / Industry Protocol IDs: PCYC-1116-CA, 2012-003968-44, NCT01724346
6.	A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 65 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CR100967, PCI-32765MCL3002, U1111-1137-0389, 2012-004056-11, NCT01776840
7.	A Long-term Extension Study of PCI-32765 (Ibrutinib) Phase: Phase III Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CR100955, 2012-004225-24, PCI-32765CAN3001, NCT01804686
8.	Pilot Study to Determine Effects of the Btk Inhibitor PCI-32765 on Leukemia Cell Kinetics and Trafficking, Using Heavy Water Labeling in Subjects With CLL and SLL Phase: Phase II, Phase I Type: Treatment Status: Active Age: 65 and over Sponsor: Other Protocol IDs: 2012-0086, NCT01752426
9.	Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: PCYC-1111-CA, PCI-32765, NCT01478581
10.	PCI-32765 for Special Cases of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NHLBI Protocol IDs: 120035, 12-H-0035, NCT01500733
11.	PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: OSU-11133, NCI-2012-00560, NCT01589302
12.	Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 12-015, NCT01614821
13.	A Multicenter Phase 2 Study of PCI-32765 (Ibrutinib) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: PCYC-1117, 2012-004476-19, NCT01744691
14.	A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CR100956, 2012-004097-26, PCI-32765FLR2002, NCT01779791
15.	Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2013-00826, OSU 12200, 9268, U01CA076576, NCT01841723
16.	Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: OSU-10052, NCI-2011-03293, NCT01479842
17.	A Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With CD20-Positive B-Cell Non Hodgkin Lymphoma Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CR100844, PCI-32765DBL1002, 2012-000546-35, NCT01569750
18.	A Study to Evaluate the Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Patients With Recurrent Mature B-Cell Neoplasms Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 20 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CR100896, PCI-32765-JPN-101, NCT01704963
19.	Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2013-00792, A051103, U10CA031946, NCT01829568